Athena A Schepmoes
Overview
Explore the profile of Athena A Schepmoes including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
62
Citations
1825
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Xu G, Grimes T, Grayson T, Chen J, Thielen L, Tse H, et al.
Nat Commun
. 2022 Mar;
13(1):1159.
PMID: 35241690
Currently, no oral medications are available for type 1 diabetes (T1D). While our recent randomized placebo-controlled T1D trial revealed that oral verapamil had short-term beneficial effects, their duration and underlying...
12.
Nakayasu E, Gritsenko M, Piehowski P, Gao Y, Orton D, Schepmoes A, et al.
Nat Protoc
. 2021 Jul;
16(8):3737-3760.
PMID: 34244696
Mass-spectrometry-based proteomic analysis is a powerful approach for discovering new disease biomarkers. However, certain critical steps of study design such as cohort selection, evaluation of statistical power, sample blinding and...
13.
Joshi S, Nechiporuk T, Bottomly D, Piehowski P, Reisz J, Pittsenbarger J, et al.
Cancer Cell
. 2021 Jun;
39(7):999-1014.e8.
PMID: 34171263
Our study details the stepwise evolution of gilteritinib resistance in FLT3-mutated acute myeloid leukemia (AML). Early resistance is mediated by the bone marrow microenvironment, which protects residual leukemia cells. Over...
14.
McDermott J, Arshad O, Petyuk V, Fu Y, Gritsenko M, Clauss T, et al.
Cell Rep Med
. 2020 Sep;
1(5).
PMID: 32954372
[This corrects the article PMC7289043.].
15.
Lee J, Shi T, Petyuk V, Schepmoes A, Fillmore T, Wang Y, et al.
Cancer Epidemiol Biomarkers Prev
. 2020 Jun;
29(8):1665-1672.
PMID: 32532828
Background: Approximately 85% of the U.S. military active duty population is male and less than 50 years of age, with elevated levels of known risk factors for oropharyngeal squamous cell...
16.
McDermott J, Arshad O, Petyuk V, Fu Y, Gritsenko M, Clauss T, et al.
Cell Rep Med
. 2020 Jun;
1(1).
PMID: 32529193
In the absence of a dominant driving mutation other than uniformly present TP53 mutations, deeper understanding of the biology driving ovarian high-grade serous cancer (HGSC) requires analysis at a functional...
17.
Gao Y, Wang Y, Chen Y, Wang H, Young D, Shi T, et al.
Cancers (Basel)
. 2020 May;
12(5).
PMID: 32429558
Although ~40% of screen-detected prostate cancers (PCa) are indolent, advanced-stage PCa is a lethal disease with 5-year survival rates around 29%. Identification of biomarkers for early detection of aggressive disease...
18.
Ilhan Z, DiBaise J, Dautel S, Isern N, Kim Y, Hoyt D, et al.
NPJ Biofilms Microbiomes
. 2020 Mar;
6(1):12.
PMID: 32170068
Although the etiology of obesity is not well-understood, genetic, environmental, and microbiome elements are recognized as contributors to this rising pandemic. It is well documented that Roux-en-Y gastric bypass (RYGB)...
19.
Deatherage Kaiser B, Jacobs J, Schepmoes A, Brewer H, Webb-Robertson B, Valtier S, et al.
J Med Toxicol
. 2019 Nov;
16(1):49-60.
PMID: 31677050
Introduction: Non-medical use and abuse of prescription opioids is a growing problem in both the civilian and military communities, with minimal technologies for detecting hydrocodone use. This study explored the...
20.
Stevens S, Liu T, Bahjat F, Petyuk V, Schepmoes A, Sontag R, et al.
Transl Stroke Res
. 2018 Oct;
10(4):440-448.
PMID: 30341719
Each year, thousands of patients are at risk of cerebral ischemic injury, due to iatrogenic responses to surgical procedures. Prophylactic treatment of these patients as standard care could minimize potential...